Korean Biotech Sentiment Still Shaky But IPO Recovery Seen By Year-End

Investors Eye Upcoming SK Biopharm Float Next Year

After a lackluster year so far for South Korean biotech IPOs amid disappointing clinical trial news, investor interest is beginning to pick up, with several companies that have been under the spotlight slated to debut on the market in the coming months.

Going public
Korean Biotech IPOs Seen Picking Up • Source: Shutterstock

Initial public offerings in the South Korean biotech sector are poised to recover from a nearly year-long slump, as several companies which have been under investors’ radars are slated to launch IPOs from this month.

So far, nine bioventures have launched floats in the first 10 months of this year, a sharp contrast to the...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from South Korea

More from Focus On Asia